Group 1 - The company Sanofi Bio (300298) announced a share buyback program, having repurchased a total of 6.8275 million shares as of October 31, 2025 [1] - The repurchased shares account for 1.22% of the company's current total share capital [1] - The total amount spent on the share buyback is 139 million yuan, excluding transaction fees [1]

Core Viewpoint - Sanofi Bio announced a share buyback plan, indicating confidence in its financial health and future prospects [1] Group 1 - The company has repurchased a total of 6.8275 million shares, which represents 1.22% of its current total share capital [1] - The total amount spent on the share buyback is 139 million yuan, excluding transaction fees [1]

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-081 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于回购公司部分股份的进展公告 一、回购股份的进展情况 截至 2025 年 10 月 31 日，公司通过股份回购专用证券账户以集中竞价交易 方式累计回购公司股份 6,827,500 股，占公司当前总股本的比例为 1.22%，本次 回购股份的最高成交价为 21.39 元/股，最低成交价为 18.97 元/股，成交总金额为 139,091,595.98 元（不含交易费用）。本次回购符合公司既定的回购方案及相关法 律法规的要求。 二、其他说明 （一）公司回购股份的时间、回购股份的数量、回购股份价格及集中竞价交 易的委托时段均符合《深圳证券交易所上市公司自律监管指引第 9 号——回购股 份》等法律法规的相关规定。 1、公司未在下列期间内回购公司股份： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； 本公司及董事会全体成员保证信息披露的内容真实 ...

Core Insights - The company Sanofi Biotech is showcasing its advancements in continuous glucose monitoring (CGM), chronic disease digital management, artificial intelligence, globalization strategy, and diabetes public welfare practices ahead of World Diabetes Day [1][4] Group 1: CGM Market Dynamics - The CGM market is experiencing a shift from intermittent to continuous monitoring, with CGM products providing real-time data for diabetes management, representing a significant growth opportunity [4] - Intense price competition is evident in the domestic CGM market, with prices dropping significantly; for instance, during the "Double 11" shopping event, CGM prices fell to around 100 yuan per unit, a substantial decrease from two years ago [4] - The company emphasizes a strategy focused on "technology-driven and reasonable pricing," aiming to enhance sensor performance and optimize production processes to lower costs while increasing service value [4][5] Group 2: Innovation and Healthcare Integration - The introduction of large models for data interpretation aims to enhance data collection accuracy, with capabilities such as precise food recognition [5] - The company has supported over 500 grassroots medical institutions nationwide, improving chronic disease management through equipment empowerment, talent training, and data platform development [6] Group 3: International Expansion and Challenges - The company is pursuing a dual strategy of maintaining domestic market share while expanding internationally, with overseas revenue reaching 999.7 million yuan, accounting for 44% of total revenue by mid-2025 [7] - In Africa, the company exports 40,000 glucose monitoring devices monthly, with projected sales in the region expected to exceed 160 million yuan by 2026 [7] - The company faces patent challenges, including a lawsuit with Roche that impacted quarterly net profit by 136 million yuan, but continues to see double-digit growth in both traditional and CGM business segments [7][8]

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-080 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于控股股东部分股份质押展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于近日接到公司控股股东、 实际控制人李少波先生的通知，获悉其所持有本公司的部分股份办理了质押展期 业务，现将有关情况说明如下： 一、股东股份质押展期的基本情况 | 股 东 | 是否为控股 股东或第一 | 本次质押展 | 占其所持 | 占公司总 | 是否为限售股 | | 是否 为补 | | | 原质押 | | 展期后质押 | | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名 | 大股东及其 | 期股份数量 | 股份比例 | 股本比例 | （如是，注明限 | ...

Core Insights - The company reported a revenue of 3.453 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 8.52%, which aligns with expectations [1] - The net profit attributable to shareholders was 211 million yuan, a decline of 17.36% year-on-year, while the non-recurring net profit was 180 million yuan, down 22.13% year-on-year, falling short of expectations due to a one-time payment of 19 million USD related to patent licensing [1][2] Revenue Trends - In Q3 alone, the company achieved a revenue of 1.19 billion yuan, marking a year-on-year increase of 13.4%, with a trend of increasing revenue growth observed since the beginning of 2025 [2] - Both traditional and Continuous Glucose Monitoring (CGM) businesses experienced double-digit growth year-on-year, with steady revenue growth from subsidiaries PTS and Trividia [2] - The company anticipates positive contributions to performance from its second-generation CGM products and expansion into Southeast Asia and Europe [2] Patent and Legal Developments - Trividia signed a cross-licensing and settlement agreement with Roche on October 2, resulting in a net payment of 19 million USD, which impacted Q3 net profit [2] - Excluding this one-time impact, the net profit attributable to shareholders for Q3 would have been 1.05 billion yuan, reflecting an 82% year-on-year increase, while the net profit for the first three quarters would show a 12% year-on-year growth [2] - The company plans to appeal a temporary injunction related to iCan CGM patents in Europe and will explore strategies for the second-generation products' market entry [2] Profit Forecast and Valuation - Due to litigation impacts, the company has revised its net profit forecasts for 2025 and 2026 down by 25.8% and 12.5% to 298 million yuan and 439 million yuan, respectively [3] - The current stock price corresponds to a price-to-earnings ratio of 35.9 times for 2025 and 24.4 times for 2026 [3] - Despite the profit forecast adjustments, the company maintains a leading position in blood glucose monitoring, with a target price reduction of 7% to 26 yuan, indicating a potential upside of 36.1% from the current stock price [3]

Core Viewpoint - The company reported a strong revenue growth in Q3 2025, but net profit declined significantly due to a one-time patent payment, indicating underlying business strength when excluding this impact [4][5]. Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 3.453 billion yuan, a year-on-year increase of 8.52%, while net profit attributable to shareholders was 211 million yuan, down 17.36% [4]. - In Q3 2025, the company recorded a revenue of 1.190 billion yuan, reflecting a year-on-year growth of 13.40%, but net profit dropped by 47.55% to 30 million yuan due to a one-time payment of 19 million USD (approximately 136 million yuan) related to a patent settlement [4][5]. Business Segments - The Continuous Glucose Monitoring (CGM) business has become a key driver of growth, with the company on track to meet its annual sales targets. A differentiated strategy is employed, focusing on cost-effective first-generation products and high-end second-generation products [6]. - The domestic BGM business continues to show steady growth, while the overseas market is seeing positive developments, particularly in Europe and the Middle East, where CGM products are gaining insurance coverage [6]. Market Challenges - The company faces short-term uncertainties due to a patent lawsuit initiated by Abbott in Europe, which affects the sales of the first-generation CGM products in certain countries. However, the second-generation products are not impacted, and the company is actively evaluating promotional strategies for these products in Europe [7]. - The overseas subsidiaries, particularly Trividia, are showing continuous revenue growth, and there is a noticeable improvement in the operations of PTS. The company has established a global sales network and brand resources, indicating potential for successful international expansion [8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company's operations are stable and improving, although profits are temporarily pressured by patent licensing fees [4] - The company is a leader in the blood glucose monitoring industry, with rapid growth in new product CGM revenue and successful overseas expansion [6] Financial Summary - For 2023, the company is expected to achieve a revenue of 4,059 million RMB, with a year-on-year growth rate of 44.26% [5] - The projected revenue for 2024 and 2025 is 4,443 million RMB and 4,927 million RMB, respectively, with growth rates of 9.47% and 10.89% [5] - The net profit attributable to the parent company for 2023 is forecasted at 284 million RMB, with a significant decline of 34% year-on-year [5] - The net profit for 2024 and 2025 is expected to be 326 million RMB and 303 million RMB, reflecting growth rates of 14.73% and a decline of 7.17% [5] - The company’s earnings per share (EPS) for 2023 is projected at 0.51 RMB, with a slight increase to 0.58 RMB in 2024 and a decrease to 0.54 RMB in 2025 [5] Market Performance - In the first three quarters of 2025, the company achieved a revenue of 3,450 million RMB, a year-on-year increase of 8.5%, while the net profit attributable to the parent company was 210 million RMB, down 17.4% year-on-year [6] - The third quarter alone saw a revenue of 1,190 million RMB, with a year-on-year growth of 13.4%, but the net profit dropped significantly by 47.5% to 30 million RMB [6] - The decline in profit for Q3 was primarily due to the impact of patent licensing fees from Roche, which affected the net profit by approximately 140 million RMB [6] Profitability and Valuation - The company's gross margin for Q3 was 43.3%, down 12.1 percentage points year-on-year, but remained stable when excluding the impact of Roche's patent fees [6] - The projected price-to-earnings (P/E) ratios for 2025 and 2026 are 35.42 and 21.07, respectively, indicating a potential for valuation improvement [5][6]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return exceeding the market benchmark by more than 15% over the next 6-12 months [5][13]. Core Insights - The company's revenue for the first three quarters of 2025 reached 3.453 billion yuan, a year-on-year increase of 8.52%, while the net profit attributable to shareholders was 211 million yuan, a decline of 17.36% [1]. - In Q3 2025, the company achieved revenue of 1.190 billion yuan, up 13.40% year-on-year, but the net profit attributable to shareholders fell by 47.55% due to a one-time payment of 19 million USD (approximately 136 million yuan) related to a patent settlement with Roche [1][2]. - Excluding the one-time patent fee, the company's underlying profit showed strong growth, with a net profit of 105 million yuan in Q3 2025 [2]. Summary by Sections Revenue and Profitability - The company’s CGM (Continuous Glucose Monitoring) business is a key driver of growth, with strong performance in both domestic and international markets. The company aims to achieve its annual sales target [2]. - The traditional BGM (Blood Glucose Monitoring) business continues to grow steadily in China [2]. Market Position and Strategy - The company has adopted a differentiated competitive strategy, focusing on cost-effective first-generation products and high-end second-generation products. This approach has led to a reduction in losses for domestic operations and gradual improvement in profitability [2]. - The company is making progress in obtaining insurance coverage for its CGM products in Europe and the Middle East, laying the groundwork for future sales growth [2]. Financial Forecasts - The net profit forecast for 2025 has been revised down to 288 million yuan, a 23% decrease from the previous estimate of 374 million yuan. However, the forecasts for 2026 and 2027 remain at 468 million yuan and 564 million yuan, respectively [3][4]. - The report provides a detailed financial summary, including projected revenues and profits for the years 2023 to 2027, indicating a growth trajectory despite short-term challenges [4][9].

Summary of Sanofi Biologics Q3 2025 Earnings Call Company Overview - **Company**: Sanofi Biologics - **Industry**: Biopharmaceuticals, specifically focusing on Continuous Glucose Monitoring (CGM) products Key Points Financial Performance - Q3 2025 revenue reached **1.19 billion CNY**, a year-on-year increase of **13.4%** [3] - Net profit attributable to shareholders was **30 million CNY**, a decline of **47.5%** primarily due to cross-licensing fees with Trividia and Roche [3][5] - Excluding these fees, net profit for Q3 would have increased by over **82%** [2][3] Business Segments - **Traditional Business**: - Q3 revenue growth exceeded **10%**, showing robust performance [6] - **CJM Business**: - Revenue increased by over **80%** year-on-year, continuing to reduce losses [6] - **Overseas Market**: - Trividia's market share improved, with revenue growth quarter-on-quarter [6] CGM Product Sales - CGM products generated approximately **80 million CNY** in overseas sales in the first three quarters, with a gross margin exceeding **50%** [7] - Sales in Europe are temporarily affected by a patent lawsuit from Abbott, which has led to a sales halt in certain countries [7][8] - The company plans to launch a second-generation CGM product in the U.S. with a budget of **20 million USD**, unaffected by the European lawsuit [10] Legal Challenges - Abbott filed two patent lawsuits against Sanofi, one of which resulted in a temporary sales ban in several European countries [8][9] - The company is appealing the decision and evaluating strategies for the second-generation product to mitigate legal risks [9] Future Outlook - The company anticipates a **4-5 times** increase in CGM sales in unaffected countries like the UK and Spain in 2026, contingent on the success of the appeal against the temporary ban [7] - Overall sales for the year are expected to exceed **400 million CNY**, with a strong performance in the domestic market despite ongoing losses in CGM [11] Cost Management and Profitability - The gross margin for Q3 was impacted by the **19 million USD** patent fee, but is expected to stabilize around **63.5% to 64%** when excluding this cost [17] - Future gross margins are projected to improve through cost reduction and pricing adjustments [18] Market Strategy - The company employs a differentiated pricing strategy across various online platforms to cater to different consumer segments [12] - Domestic government subsidies are decreasing, with a shift towards consumer vouchers [13] BGMI and PTS Business - BGMI business is integrated into traditional business metrics, showing growth above **5-10%** for the year [14] - PTS is nearing completion of capacity optimization, with expectations for improved profitability in the upcoming quarters [15] User Demographics - Domestic repurchase rate is approximately **35-40%**, with type 2 diabetes patients constituting **60-70%** of the user base [21] Challenges - The company faces significant legal challenges from major competitors, which could impact its growth trajectory in the European market [22]